Beijing Memorial Pharmaceutical Research and Development Co.,Ltd.
+86 15810509002
Lang. :
English
中 文
☰
Home
Semaglutide API
Main Business
International Purchasement of Comparator
Exportation of R&D Drugs
Comparator Import & Export
Storage and Logistics of Investigational Product
Repackage of The Investigational Product
Clinical Trial Subjects Recruitment
R&D Products
News
Latest News
NDA News
Clinical News
Industrial News
Company Update
About Us
About CliniExpert
R&D center
Production base
Big Events
Photo Wall
Clinical Viewpoint
Talent Recruitment
Home
News
· R&D Products
Gefitinib
CliniExpert
•
2019/11/04
274
•
0
吉非替尼
Return
Hot Info
FDA Approves Lynkuet (elinzanetant) for Moderate to Severe Hot Flashes Due to Menopause
FDA Approves Javadin (clonidine hydrochloride) Oral Solution for the Treatment of Hypertension
FDA Approves Epioxa (riboflavin 5’-phosphate) Ophthalmic Solution for the Treatment of Keratoconus
FDA Approves Ferabright (ferumoxytol injection) Contrast Agent for Magnetic Resonance Imaging of the Brain
FDA Approves Lasix ONYU (furosemide) for Treatment of Edema in Heart Failure
FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
FDA Approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the Treatment of H. pylori Infection in Adults
FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
PellePharm Completes Enrollment Of Pivotal Phase 3 Clinical Trial Of Patidegib Topical Gel In Patients With Gorlin Syndrome
Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
15810509002
